Low-Dose Ketamine for Social Anxiety Disorder: Preliminary Evidence

Low dose ketamine for anxiety has shown early, limited evidence of reducing social anxiety symptoms, but it is not an established first-line treatment for social anxiety disorder. The strongest direct evidence comes from a small randomized study, while larger trials are still needed to clarify who may benefit, how long any benefit lasts, and how treatment should be combined with psychotherapy.

Social anxiety disorder involves persistent fear of social situations where a person expects scrutiny or embarrassment. According to the National Institute of Mental Health, an estimated 12.1% of U.S. adults experience social anxiety disorder at some point in their lives.

Standard care commonly includes cognitive behavioral therapy, especially exposure-based CBT, and medicines such as selective serotonin reuptake inhibitors. Ketamine remains an area of clinical research and requires individualized medical assessment and monitoring.

What the direct social anxiety research found

A small double-blind, placebo-controlled crossover trial evaluated subcutaneous ketamine in people with treatment-refractory social anxiety disorder or generalized anxiety disorder. The researchers reported improvement in anxiety ratings after ketamine, with effects beginning within hours for some participants. The social anxiety subgroup was small, which limits how confidently the results can be applied to the wider population.

The study is available through PubMed. It is useful because it directly studied social anxiety, but it does not establish an ideal dose, maintenance schedule, or long-term safety profile for this condition.

An open-label follow-up study reported continued symptom improvement among some prior responders receiving repeated treatment. Open-label results can be influenced by expectations and do not provide the same level of certainty as a blinded comparison. They support further research rather than a definitive treatment recommendation.

Why ketamine is being studied for anxiety

Ketamine is an NMDA receptor antagonist, meaning it affects one part of the brain's glutamate signaling system. Researchers are studying whether this action can temporarily change plasticity in circuits involved in threat learning, emotional regulation, and avoidance.

Social anxiety has been associated with heightened responses to perceived social threat and difficulty disengaging from feared evaluation. This does not mean one brain finding explains every person's symptoms. It does provide a rationale for studying treatments that may affect fear learning and regulatory circuits.

Researchers have proposed that ketamine could be most useful when paired with structured psychotherapy, particularly exposure-based work. The idea is that treatment may create a period in which new learning is easier to consolidate. This remains a hypothesis, not a confirmed clinical protocol. Readers interested in this approach can review ketamine integration therapy and the discussion of neuroplasticity and ketamine.

Safety and treatment questions to consider

Ketamine can cause dissociation, changes in perception, sedation, nausea, and temporary increases in blood pressure or heart rate. The U.S. Food and Drug Administration labeling for ketamine describes cardiovascular and psychological effects that require clinical judgment and appropriate monitoring. See the FDA prescribing information for Ketalar for the approved anesthetic product's safety information.

For someone with social anxiety, temporary changes in perception or physical sensations may feel especially uncomfortable. A calm setting, clear preparation, and a plan for follow-up can matter, but they do not remove the need for clinical screening.

Medication interactions and alcohol use are important topics to raise before treatment. Review ketamine drug interactionsketamine and alcohol safety risks, and common ketamine side effects for general educational context.

Questions to discuss with a clinician

Ask whether social anxiety disorder is the main diagnosis or part of a broader condition, what evidence supports ketamine for your situation, and how outcomes would be measured. Ask what monitoring occurs during treatment, how current medications or health conditions affect suitability, and what the plan is if symptoms return. It is also reasonable to ask how psychotherapy, especially exposure work, fits into the overall plan.

People seeking a rapid intervention should weigh that possibility against the limited direct evidence. People who have not yet had an adequate course of exposure-based CBT or first-line medication may want to discuss those options first. Ketamine may be a research-informed option for selected patients, not a universal answer to social anxiety.